<br>        Inclusion Criteria:<br><br>          -  Personally signed and dated informed consent document.<br><br>          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,<br>             and other study procedures.<br><br>          -  Male or female, =18 years of age<br><br>          -  Weight =40 kg at Screening<br><br>          -  Cancer diagnosed as having metastasized to bone or multiple myeloma.<br><br>          -  Imaging confirmation of bone metastasis at Screening or within 120 days prior to the<br>             Screening visit.<br><br>          -  Expected to require daily opioid medication throughout the course of the study.<br><br>          -  Willing to not use prohibited medications (including NSAIDs) throughout the duration<br>             of the study.<br><br>          -  Average Pain Score =5 at Screening for the index bone metastasis cancer pain site.<br><br>          -  Patient's Global Assessment of Cancer Pain of fair, poor or very poor at<br>             Screening.<br><br>          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1, or 2 at<br>             Screening.<br><br>          -  Adequate bone marrow, renal and liver function at Screening.<br><br>          -  International Normalized Ratio (INR) or prothrombin time (PT) <1.5 x ULN at Screening<br>             unless being treated with anticoagulant medication.<br><br>          -  Females must either be not of childbearing potential or, if of childbearing potential<br>             and at risk for pregnancy, must be willing to use at least one highly effective method<br>             of contraception throughout the study and for 112 days (16 weeks) after the last dose<br>             of assigned subcutaneous study medication.<br><br>        Exclusion Criteria:<br><br>          -  Pain related to an oncologic emergency.<br><br>          -  Brain metastasis or leptomeningeal metastasis.<br><br>          -  Presence of hypercalcemia at Screening.<br><br>          -  Pain primarily classified as not predominantly related to a bone metastasis.<br><br>          -  Systemic treatment for the primary malignancy or bone metastasis started within 30<br>             days of the Baseline Assessment Period.<br><br>          -  Chemotherapies associated with peripheral neuropathy (ie, paclitaxel, docetaxel,<br>             oxaliplatin, cisplatin, vincristine, thalidomide or bortezomib) are prohibited during<br>             the study from 30 days prior to the first day of the Baseline Assessment Period to<br>             Week 48.<br><br>          -  Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone<br>             metastasis within 30 days of the Baseline Assessment Period.<br><br>          -  Concurrent adjuvant analgesics unless started at least 30 days prior to the start of<br>             the Baseline Assessment Period and maintained at a stable dose.<br><br>          -  Diagnosis of osteoarthritis of the knee or hip or findings consistent with<br>             osteoarthritis in the shoulder.<br><br>          -  History of significant trauma or surgery to a major joint within one year prior to<br>             Screening.<br><br>          -  History of osteonecrosis or osteoporotic fracture.<br><br>          -  X-ray evidence at Screening of: 1) rapidly progressive osteoarthritis, 2) atrophic or<br>             hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4) spontaneous<br>             osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic fracture.<br><br>          -  Signs and symptoms of clinically significant cardiac disease.<br><br>          -  Evidence of orthostatic hypotension at Screening or at Baseline prior to<br>             randomization.<br><br>          -  Diagnosis of a transient ischemic attack in the 6 months prior to Screening or<br>             diagnosis of stroke with significant residual deficits.<br><br>          -  History, diagnosis, or signs and symptoms of clinically significant neurological<br>             disease.<br><br>          -  Total impact score of >7 on the Survey of Autonomic Symptoms (SAS) at Screening.<br><br>          -  Past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one<br>             year prior to Screening.<br><br>          -  History of significant alcohol, analgesic, or narcotic substance abuse within the six<br>             months prior to Screening.<br><br>          -  Planned surgical procedure during the duration of the study.<br><br>          -  Considered unfit for surgery or not willing to undergo joint replacement surgery if<br>             required.<br><br>          -  Known hypersensitivity to opioids or an underlying medical condition contraindicating<br>             opioid use.<br><br>          -  History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal<br>             antibody or IgG-fusion protein.<br><br>          -  Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor<br>             antibody.<br><br>          -  Presence of drugs of abuse, prescription medications without a valid prescription or<br>             other illegal drugs at Screening.<br><br>          -  Positive Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) tests at<br>             Screening indicative of current infection.<br><br>          -  Investigational site staff members and their family members, or Pfizer employees<br>             directly involved in the conduct of the trial.<br><br>          -  Participation in other studies involving investigational drug(s) within 30 days (or 90<br>             days for investigational biologics) before Baseline Assessment Period and/or during<br>             study participation.<br><br>          -  Pregnant female subjects; breastfeeding female subjects; female subjects of<br>             childbearing potential who are unwilling or unable to use one (1) highly effective<br>             method of contraception throughout the study and for 112 days after last dose of<br>             investigational product.<br><br>          -  Other severe acute or chronic medical or psychiatric condition or laboratory<br>             abnormality.<br>